Inspire Medical Systems (INSP) reported mixed results for the nine months ended September 30, 2025 (Q3 FY2025). Revenue grew strongly by 14.2% year-over-year to \(642.9M, predominantly driven by the US market (95.7% of revenue). However, net profitability was severely eroded by sharply increasing operating expenses. Nine-month Net Income plummeted 49.0% to \)9.3M (\(18.3M in 2024), with Operating Income dropping to \)4.84M (\(18.29M in 2024). The primary pressure point is SG&A expense growth, which outpaced revenue gains, and a substantial rise in Advertising (\)82.1M YTD vs. $72.1M prior year).
**
...